Clinical trial C4891026
An interventional safety and efficacy phase 1b/2, open-label study to investigate tolerability, PK, and antitumor activity of vepdegestrant (AVR-471/PF-07850327), an oral proteolysis targeting chimera, in combination with PF-07220060 in participants aged 18 years and older with ER+/HER2- advanced or metastatic breast cancer.
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Pfizer |
| EudraCT Identifier | 2023-508130-33-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06206837 |
| Last update |